Investors with significant funds have taken a bearish position in Vertex Pharmaceuticals (NASDAQ:VRTX), a development that retail traders should be aware of. This was brought to our attention today ...
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results